0LB2 Stock Chart & Stats
$47.68
$0.00(0.00%)
At close: 4:00 PM EDT
$47.68
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$34.57 - $59.74
Previous CloseN/A
Volume1.00
Average Volume (3M)15.00
Market Cap
$2.59B
Enterprise Value$2.64K
Total Cash (Recent Filing)$384.24M
Total Debt (Recent Filing)$40.90M
Price to Earnings (P/E)―
Beta0.63
Next Earnings
Aug 04, 2026EPS Estimate
0.42Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.51
Shares Outstanding58,039,722
10 Day Avg. Volume7
30 Day Avg. Volume15
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)2.64
Price to Sales (P/S)3.90
P/FCF Ratio61.00
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$63.50Price Target Upside33.18% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)2.49
Revenue Forecast (FY)$867.18M
Bulls Say, Bears Say
Bulls Say
Strong Balance SheetExtremely low leverage and a sizable equity base provide durable financial flexibility to fund R&D, support commercialization, absorb setbacks, and pursue partnerships or acquisitions without reliance on debt markets. This reduces refinancing risk and preserves strategic optionality over months to years.
Consistent Cash GenerationSustained positive operating and free cash flow, despite recent GAAP losses, underpins the company’s ability to fund operations, milestone payments, and pipeline activity internally. Reliable cash conversion improves resilience versus peers and lowers need for dilutive financing.
Pipeline Expansion Via NV-5138 (SPN-820) AcquisitionSecuring exclusive rights and data for SPN-820 materially strengthens Supernus’s CNS pipeline, aligning with core therapeutic focus. Ownership of the asset and control of development decisions provide a potential mid-term product growth vector and strategic commercialization optionality if trials succeed.
Bears Say
Ongoing GAAP LossesA sustained GAAP loss profile weakens return metrics and can erode shareholder equity over time if not reversed. Persistent losses constrain reinvestment, may force reliance on cash reserves or equity financing for growth, and complicate comparisons to peers on reported profitability.
Rising Operating ExpensesA structurally higher cost base driven by elevated R&D and SG&A requires sustained revenue expansion to protect margins. If revenue growth slows, elevated fixed spending will compress GAAP profitability and free cash flow, increasing execution demands on commercial and development programs.
Supply & Regulatory Timing RiskDependence on a second supplier and pending regulatory approvals creates a structural risk to product availability and revenue recovery. Protracted FDA review or manufacturing setbacks could limit patient starts, hamper prescription conversion, and delay full commercial normalization over the next 6–12+ months.
Supernus Pharmaceuticals News
0LB2 FAQ
What was Supernus Pharmaceuticals’s price range in the past 12 months?
Supernus Pharmaceuticals lowest share price was $34.57 and its highest was $59.74 in the past 12 months.
What is Supernus Pharmaceuticals’s market cap?
Supernus Pharmaceuticals’s market cap is $2.59B.
When is Supernus Pharmaceuticals’s upcoming earnings report date?
Supernus Pharmaceuticals’s upcoming earnings report date is Aug 04, 2026 which is in 2 days.
How were Supernus Pharmaceuticals’s earnings last quarter?
Supernus Pharmaceuticals released its earnings results on May 05, 2026. The company reported $0.602 earnings per share for the quarter, beating the consensus estimate of $0.298 by $0.304.
Is Supernus Pharmaceuticals overvalued?
According to Wall Street analysts Supernus Pharmaceuticals’s price is currently Undervalued.
Does Supernus Pharmaceuticals pay dividends?
Supernus Pharmaceuticals pays a Notavailable dividend of $0.285 which represents an annual dividend yield of N/A. See more information on Supernus Pharmaceuticals dividends here
What is Supernus Pharmaceuticals’s EPS estimate?
Supernus Pharmaceuticals’s EPS estimate is 0.42.
How many shares outstanding does Supernus Pharmaceuticals have?
Supernus Pharmaceuticals has 58,039,722 shares outstanding.
What happened to Supernus Pharmaceuticals’s price movement after its last earnings report?
Supernus Pharmaceuticals reported an EPS of $0.602 in its last earnings report, beating expectations of $0.298. Following the earnings report the stock price went up 6.424%.
Which hedge fund is a major shareholder of Supernus Pharmaceuticals?
Currently, no hedge funds are holding shares in GB:0LB2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Supernus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$63.50 (33.18% Upside)
$63.50 (33.18% Upside)
Blogger Sentiment
Bullish
GB:0LB2 Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
40.63%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.39%
Trailing 12-Months
Company Description
Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa for those experiencing similar off periods. Other offerings include GOCOVRI, which targets dyskinesia in PD patients, and Osmolex ER, used for Parkinson's disease and drug-induced extrapyramidal reactions in adults. MYOBLOC, a Type B toxin, is indicated for cervical dystonia and sialorrhea in adults. Beyond its commercial portfolio, Supernus is actively developing several investigational therapies. These include Qelbree (SPN-812), which has successfully completed Phase III trials for ADHD. SPN-830, a late-stage drug/device combination, aims to prevent off episodes in PD patients. SPN-817 is a novel compound in Phase I trials for severe epilepsy. SPN-820 is undergoing Phase II trials for resistant depression, and SPN-443 and SPN-446 are in earlier, preclinical stages for various CNS indications. Products are distributed through a network of pharmaceutical wholesalers, specialty pharmacies, and authorized distributors. Established in 2005, Supernus Pharmaceuticals is headquartered in Rockville, Maryland.
0LB2 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum across multiple products with robust revenue growth (total revenue +39% YoY; growth products +56% YoY), improving non-GAAP profitability, a healthy cash position (~$384M) and an advancing R&D pipeline. Offsetting these positives are meaningful increases in operating expenses (combined R&D and SG&A up ~40.8% YoY), ongoing GAAP losses (albeit reduced), supply constraints and conversion challenges for Onepco, and timing / regulatory risk related to bringing a second supplier online. Management reiterated full-year guidance ranges and emphasized continued focus on corporate development and supply backups. Overall, the positive top-line growth, improved profitability metrics, strong product-specific trends and solid balance sheet outweigh the near-term expense and supply risks.View all GB:0LB2 earnings summaries0LB2 Stock 12 Month Forecast
Average Price Target
$63.50
▲(33.18% Upside)